Gene therapy using ‘zinc fingers’ may help treat Alzheimer’s disease, animal study shows

Scienmag

Treatment involving a single injection has long-lasting effects BOSTON – Researchers have used a genetic engineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition.

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. GAITHERSBURG, Md., 16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. protein-based biologics) and vaccine treatments.

Nobell Foods Receives $75 Million In Funding to Commercialize Their Plant-Based Cheese

XTalks

This cheese is different from other plant-based cheeses because the start-up uses genetically engineered soybeans to produce plant-based casein. Richani said that they use plants because they are the cheapest form of protein they can get.

AI-designed serotonin tracker could help develop neurology drugs

Pharma Phorum

The US National Institutes of Health said that the research it had co-funded used AI to transform a bacterial protein into a new research tool. Tian worked with Looger’s team and used artificial intelligence to completely redesign the protein known as OpuBC to catch serotonin instead.

COVID prompts another milestone, as India clears first DNA vaccine

Pharma Phorum

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells.

DNA 83

Johns Hopkins Researchers Identify CRISPR Dimmer

The Pharma Data

A range of companies are exploring potential gene editing therapies based on a CRISPR-Cas9 system, and the ability to tune the CRISPR cut could prevent off-target editing or control the degree of a target protein’s production.

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

XTalks

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

COVID-19 Vaccines Currently Being Developed and What It All Mean for Us

Riverside Clinical Research

These structures, referred to as the S protein, can attach. An effective COVID-19 vaccine may very well be one that targets this protein. There are also genetically engineered vaccines which use RNA and DNA to copy the S protein in hopes of. There is no question that humankind requires assistance…a heavy-hitter, a formidable opponent to help. combat COVID-19. An effective vaccine is exactly that shot in the arm we need to protect ourselves.

Pfizer/BioNTech COVID jab works against Brazil variant; lab study

Pharma Phorum

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

The Pharma Data

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19.

Novartis’ Ilaris fails in late-stage COVID-19 trial

Pharma Phorum

Novartis is also working with Molecular Partners to develop therapies based on genetically engineered proteins known as DARPins. These are small proteins that are created in the lab but mimic the effect of antibodies and could be used to neutralise the SARS-CoV-2 coronavirus that causes COVID-19.

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Clinical Catch-Up: January 4-8 | BioSpace

The Pharma Data

INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the Fc domain of the immunoglobulin IgG1. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Novavax, Inc.

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

The Pharma Data

AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. SAN JOSE, Calif. , 27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc.

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers.

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Relying on independent research and development, the Company has formed gene recombination and fermentation engineering technology, and developed a number of core technologies, such as recombinant collagen, enzymatic and genetic engineering synthesis of bioactive peptides. . LAVAL, QC, Nov. 5, 2020 /PRNewswire/ – Crescita Therapeutics Inc.

Biopharma Leaders Unite To Stand With Science

The Pharma Data

mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.

Biopharma Leaders Unite To Stand With Science

The Pharma Data

mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.